A large portion of the human genome is transcribed into RNAs without known protein-coding functions, far outnumbering coding transcription units. Extensive studies of long noncoding RNAs (lncRNAs) have clearly demonstrated that they can play critical roles in regulating gene expression, development, and diseases, acting both as transcriptional activators and repressors. More recently, enhancers have been found to be broadly transcribed, resulting in the production of enhancer-derived RNAs, or eRNAs. Here, we review emerging evidence suggesting that at least some eRNAs contribute to enhancer function. We discuss these findings with respect to potential mechanisms of action of eRNAs and other ncRNAs in regulated gene expression.
Enhancers in development and diseases
Functional specialization of cell and tissue types is vital for all metazoans. This requires cells to respond to developmental and environmental cues by generating specific gene expression patterns on the basis of an identical set of genetic material. Enhancers are the principle regulatory components of the genome that enable such cell-type and cell-state specificities of gene expression. Enhancers were initially defined as DNA elements that act over a distance to positively regulate expression of protein-encoding target genes [1] . Enhancers contain specific recognition sequences required for binding of transcription factors (TFs) that regulate gene expression in a spatial and temporal fashion ( Figure 1A ). An estimated 400 000 to >1 million putative enhancers exist in the human genome [2, 3] , vastly outnumbering protein-coding genes, therefore suggesting a high complexity of enhancer utilization in gene regulation. Indeed, a precise pattern of activation of specific cohorts of enhancers is critical for cell-type development and cell lineage determination, as well as cellular responses to stimuli ( Figure 1A ,B). By contrast, genetic variance in enhancer sequences can alter TF binding, predisposing the organism to 'improper' gene expression and, ultimately, susceptibility to diseases ( Figure 1C ) [4, 5] .
Recent genomic and epigenomic advances have contributed many insights into the properties, activity, and selection of enhancer elements. Interestingly, the selection of a large fraction of cis-acting regulatory elements for enhancer activity appears to depend on relatively simple combinations of the lineage-determining transcription factors (LDTFs) for cell type identity. Through cooperative binding to closely spaced recognition motifs, LDTFs initiate binding to otherwise closed chromatin and facilitate chromatin accessibility by recruitment of ATP-dependent nucleosome remodeling complexes. Histone modifiers are recruited to deposit histone marks that demarcate enhancer regions (e.g., monomethylation of histone 3 lysine 4, H3K4me 1 ) [6] . Although a large fraction of enhancers requires cooperative binding of TFs [6, 7] , another group of enhancers is activated by sequential binding of TFs at different development stages [8] . A group of nucleosome-avid 'pioneering' TFs, exemplified by Forkhead box A (FoxA) and GATA binding protein (GATA), initiate this sequential binding to condensed chromatin to prime a 'soon-to-be' enhancer [9] . Binding of either LDTFs or pioneering factors permits the binding of other TFs and cofactors upon signal transduction events resulting in cell-type specific, signal-dependent gene expression ( Figure 2A ). For more information on the physiology, clinical implication, and biochemical and molecular perspectives of enhancers, we refer our readers to several excellent reviews [2, [10] [11] [12] .
Recent findings that enhancers can be transcribed added a new layer of complexity to gene regulation [13] . In addition to mRNAs, ncRNAs represent a highly functional class of molecules because they can possess enzymatic activity (e.g., spliceosomes, ribozyme), have structural roles (e.g., tRNA, ribosomes), and transcriptional functions (e.g., lncRNAs) [14, 15] (Box 1). Understanding how RNAs contribute to enhancer function has thus become an area of active interest. We will discuss some of the historical aspects of enhancers as transcription units and recent studies suggesting functional roles of enhancer-derived RNAs, noting similarities and differences with other classes of ncRNAs that can exert positive effects on gene regulation.
Evidence of RNA transcription from enhancers
Evidence of pervasive RNA transcription at active enhancer elements became apparent with recent advances in sequencing technology. Interestingly, several reports over the past half a century had already hinted at the existence of short-lived nuclear RNAs (Table 1) . Using pulse-chase labelling of RNA (Table 2) , Harris found that the turnover rates of RNA in the nuclei of macrophages or fibroblasts were too high to account for the relatively steady level of cytoplasmic RNA [16] . This study provided the first evidence that the majority of the nascent RNA produced in the nucleus is rapidly turned over and does not contribute to mRNAs. The discovery of pervasive enhancer transcription suggests that eRNAs, in addition to intronic RNA, are quantitatively important contributors to this rapidly degraded pool of nuclear RNA [17] . Reports of specific enhancer-derived transcription were first documented in the locus control region (LCR) of the beta-globin gene clusters [18] [19] [20] . Located 10-15 kb upstream of the gene cluster, the beta-globin LCR orchestrates temporal and spatial expression of globin genes during development. It consists of five erythroid-specific DNAse-I hypersensitivity sites (HS) ( Table 2) , and binding elements for erythroid LDTFs such as GATA binding protein 1 (GATA1), suggesting enhancer-like properties of these regions. Importantly, transcriptional initiation sites were found in several of these DNAse-I hypersensitivity regions [18] [19] [20] , and are distinct from alternative start sites of the globin gene itself [20, 21] . The description of enhancer RNA transcripts was subsequently extended to the LCR of MHC class II [22] and human growth hormone (hGH) [23] loci.
A demonstration of a broad pattern of transcription at active enhancers was uncovered by deep sequencing approaches, with total RNA sequencing ( Table 2) revealing enhancer transcription in neurons and T cells [13, 24] . Similarly, genome-wide detection of nascent RNA transcripts using Global Run-On sequencing (GRO-seq; Table  2 ) demonstrated robust expression and regulation of eRNA in macrophages, breast, or prostate cancer cells [25] [26] [27] [28] . RNA polymerase II (RNA PolII) complexes were noted to be enriched at enhancer elements [24] and to respond dynamically to signal transduction events [13, 29] . Thus, enhancer transcription is a widespread phenomenon observed across multiple cell types in different species.
Properties of eRNAs compared to mRNAs and other ncRNAs RNA-seq, chromatin immunoprecipitation (ChIP)-seq, and chromatin-conformation-capture studies (Table 2) have collectively defined the following characteristics of eRNA transcripts ( Figure 3 [27] . This group of enhancers, highlighted in blue, will be readily activated upon repeated stimulation [71] . The order from top to bottom indicates the sequential cascade of events (from stimulus activation to restoration of resting state); the distance between two histone methylation marks represents nucleosome spacing and chromatin accessibility; and brown lines on 'e' indicates enhancer-derived RNAs (eRNAs). (C) Dysregulated enhancer functions are involved in human diseases, as exemplified in breast cancer and coronary artery disease (CAD) [5, 72, 73] . Genetic variation in an enhancer (denoted as e') could alter TF binding or create or destroy functional enhancers, resulting in differential gene regulation. This is also often paralleled by differential chromosomal looping. Some of these scenarios can be directly linked to disease-associated genetic variants that occur at the DNA level of enhancers (e.g., single nucleotide polymorphism, insertion, deletion, and copy number variants). The sizes of arrowheads of genes or symbols of TFs are proportional to their expression levels or binding intensities, respectively. Box 1. Conceptual distinctions between eRNAs, 1D-eRNAs, 2D-eRNAs, lncRNAs, and ncRNA-a eRNAs are noncoding RNA transcripts produced from genomic regions that are marked by high H3K4me 1 and low H3K4me 3 histone modifications that are presumably enhancer DNA elements. eRNAs can be either polyadenylated or non-polyadenylated and appear as unidirectional (1D-eRNA) or bidirectional transcripts (2D-eRNA) in RNA-seq or GRO-seq profiles [13, [24] [25] [26] 32, 38] . lncRNAs are noncoding RNA transcripts generally longer than 200 nucleotides (nt) [74] . ncRNA-a (noncoding RNAs activating) were transcripts annotated in the GENCODE database with an average size of 800 nt, with subsequent studies showing enhancer-like properties by activating neighboring genes [43] . Although many ncRNA-a transcripts might be more suitably classified as lncRNAs because they are often spliced and frequently bear H3K4me 3 and H3K36me
3
, histone marks for gene promoters and transcription elongation, respectively [43] , some ncRNA-a transcripts are very similar to eRNAs, especially unidirectional 1D-eRNAs. Functional distinctions between these groups are not fully clarified (see Figure 3 in main text for more information). [17, 31] but are generally not spliced or polyadenylated. Polyadenylated eRNAs are generally unidirectionally transcribed from enhancers (1D-eRNA) [24] ; however, enhancers with bidirectional transcription and non-polyadenylated transcripts (2D-eRNA) are more common [24, 32] . (vi) eRNAs generally exhibit shorter half-lives compared to mRNAs and lncRNAs, but the frequency of transcription initiation of eRNAs appears comparable to Signal-dependent activation of enhancers leads to increased production of eRNAs, which interact with looping factors (e.g., cohesin complex) and facilitate/stabilize chromosomal looping between the enhancer and promoter(s) of cognate target gene(s) [28] . eRNA mediates the loading of RNA PolII, and likely the transcription initiation complex (denoted by TFIID) at the promoter of the target gene [34] . Whether chromosomal looping facilitates RNA PolII loading is unknown. (C) Transcription elongation is required for the deposition of di-methylation of histone lysine 4, or H3K4me 2 , also a histone mark for an enhancer, during signaldependent activation of de novo enhancers. The coactivator complexes generate acetylation of histones, which recruits the positive transcription elongation factor (pTEFb, orange) to promote elongation of RNA PolII. Subsequently, the elongating PolII recruits histone methyl transferases, mixed lineage leukemia complexes (MLLs), for dimethylation deposition on H3K4 at enhancers [27] . The key in panel (A) also refers to panels (B) and (C).
Review
Trends in Biochemical Sciences April 2014, Vol. 39, No. 4 [75] Using genetics models of Escherichia coli, the PaJaMa studies proposed a general mechanism for transcriptional regulation via a repressor system to control protein production of beta-galactosidase. This led to the finding of lac operator, or 'lac operon' regulatory element [76] .
This landmark study laid the groundwork for the concept of regulatory elements and the heritability of gene regulation.
1959, Harris [16] Using pulse-chase of RNA with labelled nucleotide, a large fraction of nascent RNA was shown to retain in the nucleus. In addition, the half-lives of nuclear RNA were significantly shorter compared to cytoplasmic RNA.
Harris deduced that most nuclear RNAs are likely to be non-protein-coding. In a recent Nature correspondence, Harris connected his 1959 finding with the recent studies of ncRNA [88] . Given the high number of transcribing enhancer units, the comparable frequency of transcription initiation at enhancers, and short eRNA halflives, this 1959 study is consistent with the observation of pervasive transcription at enhancer elements. 1981, Banerji et al. [1] Banerji et al. showed that a 72-repeat sequence motif from a Simian virus 40 (SV40) early gene is sufficient to increase expression of ectopic beta-globin gene by 200 fold. This DNA element is functional over long distance in an orientation-independent fashion relative to the betaglobin gene.
Discovery of cis-acting enhancer elements.
1990, Collis et al. [18]
Using nuclear run-off assays, Collis et al. identified transcription at the LCR of the beta-globin region, both in the endogenous locus in MEL (mouse erythroleukaemia) cells, as well as a mini-gene construct containing the LCR and beta-globin gene.
One of the first studies demonstrating transcription from enhancer regions.
1992, Tuan et al. [19] Using RNA protection assays in transfected recombinant plasmids, the authors identified that a noncoding RNA is transcribed from the HS2 enhancer. Only the active enhancer can direct synthesis of enhancer-derived RNA; the same group later showed that disruption of HS2-derived RNA by insertion of a transcription terminator reduced HS2 enhancer activity and expression of the target gene [39] .
This study suggested that enhancer ncRNA is only generated from active enhancer, and enhancer-derived transcription is needed for proper enhancer function.
1997, Ashe et al. [20] Using nuclear run-on assays and in situ hybridization analysis, the authors found a novel intergenic transcription from the human beta-globin locus in K562 but not in HeLa cells. Exogenous expression of the betaglobin gene in HeLa cells was sufficient to induce the expression of intergenic ncRNAs from the otherwise silent endogenous chromatin.
The intergenic ncRNA transcript displayed cell line specificity.
A 'trans' effect is implicated given that exogenous plasmid-driven transcription of the globin genes can induce intergenic ncRNA transcription at the endogenous locus. This mechanism, however, is not well understood.
2000, Gribnau et al. [77] RNA fluorescence in situ hybridization (FISH) and DNase-I sensitivity assays led to the finding that transcription activity of the human beta-globin locus correlates to its sensitivity to DNase-I.
Intergenic ncRNA transcription could play a role in maintaining open and active chromatin.
2006, Feng et al. [46] The ultraconserved region between DLX5/6 was identified to transcribe into Evf-2 ncRNA. This Evf-2 then interacts with DLX2 in vivo to activate the transcription of DLX5 and DLX6 genes.
Because ultraconserved regions are frequently enhancers [89] , this study implicated that enhancer-derived RNAs can be functionally regulatory.
'Genomic' era 2010, Kim et al. [13] ; 2010, De Santa et al. [29] ; 2011, Koch et al. [24] Enhancer transcription and transcripts are genome-wide phenomena. Enhancer-templated noncoding RNAs (eRNAs) were usually non-polyadenylated and of lower abundance compared to coding genes. Expression levels of eRNAs positively correlated to expression of nearby protein-coding genes.
Pervasive genome-wide enhancer transcription. The cognate promoter near the enhancer may be required for proper eRNA transcription. Using GRO-seq data, eRNA transcription was found to be induced by stimuli and widely distributed in the genome; their transcription correlated well with the activity of active enhancers.
eRNA transcription serves as a marker of active enhancers. Pharmacological inhibition of eRNA transcription does not inhibit enhancer-promoter looping with 3C. 2010, Orom et al. [43] ; 2013, Lai et al. [49] From transcripts annotated in GENCODE, the authors identified a cohort of lncRNAs that exhibit enhancer-like properties. Unlike eRNAs, this group of ncRNAs, termed enhancer-like lncRNAs or later as ncRNA-activating (ncRNA-a) are spliced, polyadenylated transcripts expressed from promoter-like regions (i.e., high H3K4me This is the first description of lncRNAs having enhancerlike properties. Later, the same group illustrated that ncRNA-a mediated gene regulation via modulation of the Mediator complex and chromatin looping [49] . Recent studies of other lncRNAs demonstrate novel mechanisms of gene activation, including physical interaction of lncRNA HOTTIP with methyltransferase to drive H3K4 trimethylation, and gene expression in the HoxA cluster [35] . 2013, Melo et al. that of protein-coding genes [31] . (vii) eRNAs are dynamically regulated upon signal transduction events orchestrated by signal-dependent TFs such as nuclear factor kappa-light-chain-enhancer of activated B cells (NFkB), p53, or nuclear receptors [13, [25] [26] [27] [28] [29] 31, 33, 34] . (viii) Of particular interest, signal-dependent changes in eRNA expression are highly correlated with corresponding signal-dependent transcriptional changes in promoters of nearby genes [13, 27, 28, 31] . (ix) In addition, enhancer transcripts are preferentially enriched at enhancers engaged in chromatin looping with promoters of protein-coding genes and other enhancers, which is a feature correlated with enhancer activity [36, 37] . Collectively, eRNA transcription is highly correlated to other parameters of active enhancer elements [26, 27, 38] .
Functional roles of enhancer transcription and transcripts
Whether an enhancer transcript is merely a correlation or a functional component of enhancer activity generated an active area of research. Three possibilities have been considered with respect to the physiological roles of enhancer transcription. The first possibility considers enhancer transcription as 'noise' from the spurious engagement of RNA PolII complexes to the open chromatin environment of enhancers. The second possibility hypothesizes that it is the process of transcription, not the features of the eRNA transcript itself, that is necessary for the activating functions of enhancers. The third possibility is that the RNA transcripts per se functionally contribute to enhancer activity [32] . These possibilities are not mutually exclusive.
The early investigations of enhancer transcripts from the beta-globin LCR implicated functional significance of enhancer transcription. HS2, a hypersensitivity site within the beta-globin LCR, was sufficient for erythroid-specific enhancer activity when cloned into minigene constructs [19] . The transcription start site for an enhancer transcript was found within HS2 of both the endogenous genomic locus and plasmid constructs [18, 19] . Interestingly, termination of HS2-mediated transcription by inserting a lac operator/R repressor complex downstream of the enhancer led to decreased promoter activity in a reporter construct [39] . This suggested that the transcription from HS2 is important for its neighboring promoter activity. A similar result was observed in the hGH locus when a transcription termination sequence TerF was inserted between the LCR and the promoter of hGH. Transgenic mice with this TerF insertion showed decreased expression of hGH [23] . In another line of investigation, analysis of RNA PolII localization was performed in the beta-globin locus. Expectedly, the authors found RNA PolII at the gene promoter. Surprisingly, RNA PolII was also found at the HS2 enhancer, consistent with the production of enhancer-derived RNA transcript therein. To study the role of RNA transcription in RNA PolII recruitment, cells were treated with RNA PolII elongation inhibitor 5,6-dichlorobenzimidazole (DRB). This resulted in decreased recruitment of RNA PolII to the beta-globin promoter, but not at the HS2 enhancer [40] . This implies that enhancer recruitment of RNA PolII preceded RNA PolII loading at target gene promoter. This also raised the possibilities that enhancer transcription is functionally significant for regulating RNA PolII 'loading' to the target gene promoter. This experiment, however, could not differentiate whether the RNA PolII loading was mediated by the act of enhancer transcription (i.e., RNA PolII elongation) or by the eRNA transcript itself, because both processes were inhibited by DRB.
Recently, several reports have taken new approaches to test functions of enhancer transcripts. Targeted degradation of eRNA using either RNA interference (small interfering RNA, siRNA) or DNA-RNA hybrid-induced degradation via RNase-H (i.e., antisense oligonucleotide or locked nucleic acids) proved sufficient to reduce expression of nearby protein-coding genes [28, 31, 33, 34] . To further discriminate the effects of RNA PolII transcription at the enhancer versus the eRNA transcript itself, Li et al. and Melo et al. used 'tethering' strategies [28, 33] , where eRNA transcripts were fused with RNA tags (i.e., small RNA hairpins MS2 or BoxB) to generate chimera RNAs that can be bound by a recombinant adaptor protein that could simultaneously bind to specific sequences on a reporter plasmid. This strategy enables experimental tethering of eRNA to either promoter [33] or enhancer [28] of a reporter plasmid, which was sufficient to increase transcriptional activity of the reporter gene. An alternative experimental design also supported the function of eRNA to enhancer activity. By cloning different sizes of genomic fragments from an endogenous enhancer locus, Lam et al.
showed that whereas the 'core' enhancer fragments containing LDTF binding sites were sufficient for enhancer activity, the enhancer construct containing eRNA-coding sequence had higher transcriptional activity. Importantly, the 'added' effect from the eRNA was abolished when the orientation of its coding sequence was reversed relative to the 'core' enhancer [31] . Because this inversion completely changes the sequence of the eRNA product but retains any putative TF binding sites, these results implied that the sequence of the eRNA is important for its function. Collectively, these reports suggest that, at least for some enhancers, sequence-specific eRNA transcripts can contribute to [34] and 3D-DSL, these studies found that eRNA transcripts have functional roles in regulating the transcription of neighboring coding genes.
transcript is needed for proper enhancer-promoter looping formation and gene activation.
2013, Kaikkonen et al. [27] Using genomic tools, the authors found that pharmacological inhibition of eRNA transcriptional elongation impaired mono-and di-methylation of histone H3K4 on signal-induced de novo enhancers.
RNA PolII elongation has a role independent of the eRNA transcript in modulating chromatin structure and deposition of enhancer histone marks.
Review
Trends in Biochemical Sciences April 2014, Vol. 39, No. 4 Pulse-chase A method to examine properties of cellular processes over time.
The cells are first shortly exposed to a labeled compound (pulse, e.g., radioactivity), and then to the same compound in an unlabeled form (chase). The amount of the labeled compound will change over time to reflect the effects from the interrogated cellular processes. In the context of this review, Harris measured the half-lives of nuclear and cytoplasmic RNA [16] . Global Run-On sequencing (GRO-seq) [79] A method to identify and quantify the genome-wide transcription of nascent RNA. At a given time in cells, nascent RNAs are synthesized from actively engaged RNA polymerases. GRO-seq directly measures the frequency of transcription initiation and transcriptional rate and is largely independent of the effect of RNA stability. Precision Global Run-On sequencing (PRO-seq) [56] This method is an adapted version of GRO-seq. Biotinylated nucleotides are used during in vitro transcription, enabling the mapping of the positions of the engaged RNA polymerases more precisely by sequencing. RNA 5 0 cap site analysis; 5 0 GRO-seq [31] ; PRO-cap [56] These methods introduced modifications based on GRO-seq and PRO-seq protocols. They allow mapping of the transcription initiation site and assessment of the transcription frequency by measuring 5 0 capped nascent RNAs at a given time in cells.
RNA sequencing
Total RNA-seq This method measures the overall amounts of cellular RNA species by highthroughput sequencing. Different categories of RNAs are represented proportionally to their expression levels in the final sequencing results. Because cellular RNA consists of a large amount of ribosomal RNA, rRNA removal steps are often incorporated to increase signals for mRNAs and other ncRNAs of interest. RNA-seq can also provide other information about splicing, exon inclusion, and exon exclusion, etc. Poly-A RNA-seq A modified version of total RNA-seq. This is based on using oligo-dT primer during cDNA generation and library preparation to enrich RNA species with poly A tails (e.g., most mRNAs and many lncRNAs).
Chromosomal accessibility
DNAse-I hypersensitivity assay [80] A method to assess open chromatin status. This method measures the susceptibility to DNase-I cleavage locally (e.g., beta-globin locus control region) or globally when coupled with high-throughput sequencing.
Genomic localization
Chromatin immunoprecipitation coupled with highthroughput sequencing (ChIP-seq) [81, 82] A method to study genomic localization of TFs, co-regulatory complexes, posttranslational modifications, and variants of histone marks by sequencing DNA fragments associated with these factors. The utility of this method depends on the availability of high-quality antibodies for the proteins of interest. Alternatively, a high affinity tag (i.e., a flag tag) could be fused to the protein of interest to facilitate affinity purification of the protein-chromatin complexes.
Chromosomal interaction
Chromosome conformation capture (3C) [83] A method to analyze chromosomal interactions to understand the spatial organization of the chromosomes. Because interacting genomic regions are in close 3D proximity, the likelihood of DNA ligation between two interacting regions after chemical fixation and fragmentation (e.g., restriction enzyme digestion) will be significantly higher than that between any non-interacting regions of similar linear distance. Interactions could be quantified using PCR or qPCR. Control experiments are crucial to minimize misinterpretation due to random ligations. Chromosome interaction analysis with pair end Taq sequencing (ChIA-PET) [41] A method to identify a subgroup of chromosomal interactions mediated by a specific TF of interest. Analogous to 3C, ChIA-PET detects regions of chromosomal interactions that are bound by a factor of interest (e.g., RNA PolII) by ChIP followed by 3C. The selected interactions are processed for high-throughput sequencing, which enables an unbiased, genome-wide approach for detecting long-range chromosomal interactions mediated by this factor. 3D DNA selection and ligation (3D-DSL) [5] A method to identify chromosomal interactions at pre-selected genomic regions of interest. On the basis of 3C, the digested and ligated chromatins are hybridized with a pool of oligonucleotides pre-designed to detect chromatin interactions at selected genomic regions. The limitation of resolution is dependent on the distribution of the restriction sites used for 3C and positions of the pre-designed oligonucleotides. Other methods for chromatin interactions include 4C, 5C, and Hi-C, but are not discussed here Fluorescence in situ hybridization (FISH) [84] A cytogenetic technique to detect and localize specific DNA sequences on chromosomes. A fluorescent probe (e.g., oligonucleotides or long stretches of DNAs) was predesigned to specifically hybridize to DNA/chromatin regions of interest based on sequence complementarity. Using multiple probes conjugated to multicolor fluorophores, interactions of two or more genomic regions could be approximate by tabulating the frequency of these probes being in close physical proximity by fluorescence microscopy. The resolution of this method is limited by the wavelength of the lower light spectrum (200-250 nm), which could be in the range of 10 5 to 10 6 base pairs depending on the chromatin state. enhancer-mediated transcriptional activation of neighboring coding genes.
Mechanisms of eRNA actions
A question immediately emerges as to how eRNAs might contribute to enhancer function. Chromatin interaction studies demonstrated that enhancers engaged in looping with promoters of protein-coding genes possess higher expression of eRNAs [36, 37] . These studies suggested a potential role of eRNAs in the process of proper formation of chromosomal looping between enhancers and transcription start sites (TSSs). Indeed, in nuclear receptor-regulated gene activation events, ligand treatment induces formation of chromatin looping between the enhancer and the cognate TSS, which could be measured by chromosome interaction analysis with pair end Taq sequencing ChIA-PET [41] and 3D DNA selection and ligation (3D-DSL) ( Table 2 ) [28] . More importantly, knockdown of eRNA from the estrogen receptor alpha (ERa)-bound enhancers at NR1P1 or GREB1 loci reduced enhancer-promoter interaction and concomitantly decreased coding gene activation [28] . The potential role of estrogen-induced eRNA in the modulation of chromosomal looping was suggested by the observation that eRNAs could interact with the SMC3 (structural maintenance of chromosomes 3) and RAD21 (double-strand-break repair protein rad21 homolog) subunits of the cohesin complex, which has been shown to control enhancer-promoter looping in stem cells [42] . Targeted degradation of eRNAs attenuated estrogen-induced cohesin increment to several ERa-bound enhancers, and knockdown of cohesin almost completely abolished both the observed induced looping and gene activation events [28] ( Figure 2B ). These data suggested that eRNA may play a role in the initiation or stabilization of enhancerpromoter looping, but its quantitative effect on cohesin recruitment to the enhancers remains unclear. However, Hah et al. found that reducing the amount of eRNA and coding gene transcripts through chemical inhibition of RNA PolII elongation (i.e., flavopiridol) had no significant effect on estrodiol-induced enhancer-promoter looping at the P2RY2 or the GREB1 loci, as measured by chromosomal conformation capture (3C) ( [34] . Furthermore, knockdown of CE eRNA decreased RNA PolII recruitment at the promoter and gene body of MyoD, but not at the core enhancer itself. The consequences of eRNA knockdown at the MyoD locus, as well as RNA synthesis inhibition at HS2 of the beta-globin LCR mentioned earlier [40] , suggest that eRNA transcripts facilitate RNA PolII recruitment to the promoter of the target gene ( Figure 2B ). It seems that targeted downregulation of eRNA by knockdown or inhibition of RNA PolII elongation did not affect the pre-established 'enhancer assembly', in terms of binding of TFs, recruitment of RNA PolII or enrichment in histone marks (e.g., H3K4me 1 ), suggesting that production of eRNA probably represents one of the final steps during activation of pre-established enhancers (Figure 2A) .
However, inhibition of enhancer transcription (e.g., by pharmacological inhibitor of RNA PolII elongation) impairs signal-induced de novo activation of enhancers, indicated by decreased acetylation of H3K9 [29] or attenuated mono-and di-methylation of H3K4 [27] . In the latter case, deposition of H3K4 mono-and di-methylation to enhancers is dependent on histone methyltransferases [i.e., mixed lineage leukemia-1 (MLL1), MLL2/4, and MLL3] coupled to RNA PolII elongation, but independent of the eRNA transcript [27] , suggesting a key functional role of the process of enhancer transcription, at least for some enhancer cohorts ( Figure 2C ). Collectively, these findings suggest that both enhancer transcription and the resultant enhancer RNAs can contribute to enhancer function.
Mechanism of other ncRNAs that positively regulate gene expression
In addition to eRNAs, a plethora of lncRNAs are already reported to play activating roles in gene transcription regulation [35, 43] . These lncRNAs are generally transcribed from regions exhibiting high H3K4me 3 at the promoter and H3K36me 3 at gene body (a histone mark of elongation), resembling the chromatin properties of A method to identify chromatin sites bound by an RNA of interest. The target RNA of interest is hybridized and retrieved by biotin-tagged oligonucleotides by sequence complementarity. The RNA-interacting chromatin regions can be recovered by streptavidin affinity purification and determined by highthroughput sequencing. ChIRP-seq usually uses a tiling array of oligonucleotides to enrich one RNA target and requires glutaraldehyde to irreversibly crosslink RNA targets and chromatin. Capture hybridization analysis of RNA targets coupled with sequencing (CHART-seq) [86] Another method to capture the chromatin binding sites of an RNA of interest. Similar to ChIRP, CHART uses a similar hybridization-based strategy to enrich the RNA target and its associated chromatin DNA and proteins, but uses only one cDNA oligonucleotide, which is pre-designed based on analysis of the target RNA structure. Unlike ChIRP-seq, CHART allows the use of a mild and reversible crosslinking method. Because RNA can interact with chromatin by direct DNA binding or through an indirect protein intermediate, the sensitivity of CHART-seq or ChIRP-seq to these different interactions needs to be assessed. Importantly, whether the different modalities in RNA:chromatin interactions correlate with biological significance is not known. 4 protein-coding genes [43] . They are also often spliced, polyadenylated, and unidirectionally transcribed. According to these criteria, most eRNAs and activating lncRNAs are very distinct (Box 1). However, as noted above, some transcripts derived from enhancer-like regions of the genome are polyadenylated and transcribed unidirectionally [24, 38] , and both eRNAs and lncRNAs tend to be cell-type specific [17] . Given this overlap in genomic characteristics of these two species of noncoding nuclear RNAs, there may also be overlap in mechanisms by which they influence gene expression.
Review
Although each lncRNA activator studied to date appears to function through distinct mechanisms, three general themes have emerged: (i) lncRNAs recruit activating polyadenylated and predominately unidirectional transcripts [43] . Compared to protein-coding genes, lncRNAs possess higher H3K4me 1 , higher LDTF enrichment, and lower CpG density [24] . For enhancer-derived noncoding RNAs (eRNAs), TSSs are demarcated with H3K4me1 high /H3K4me3 low modifications and low CpG density [24] .
eRNAs, in a majority, are non-polyadenylated bidirectional transcripts (2D-eRNAs), but also comprise a less common group of unidirectional transcripts (1D-eRNAs). Both 1D-and 2D-eRNAs often bear shorter half-lives (low signal from total RNA sequencing), but comparable initiation rates of transcription compared to protein-coding genes and lncRNAs, as measured by total RNA polymerase II (RNA PolII) enrichment or nascent RNA transcripts (GRO-seq). The elongating form of RNA PolII with serine 2 phosphorylation (PolII-Ser2p) mainly enriches at protein-coding genes. Chromosomal interaction studies indicated higher frequency of looping events, either enhancerpromoter, enhancer-enhancer, or promoter-promoter, at actively transcribed enhancers and protein-coding genes [36, 87] .
Trends in Biochemical Sciences April 2014, Vol. 39, No. 4 proteins and protein complexes; (ii) they mediate chromatin interactions; and (iii) they have roles in eviction of repressive machineries ( Figure 4 ). The first category constitutes the most common mechanism of activating ncRNAs ( Figure 4A ). Steroid receptor RNA activator (SRA) was the first ncRNA discovered to act as a transcriptional coactivator; it functions in the transcriptional activator complex steroid receptor coactivator-1 (SRC1) to enhance transcription mediated by steroid hormone receptors [44] . Further, Evf-2, a ncRNA generated from an ultraconserved intergenic region, was discovered to recruit TF distal-less homeobox 2 (DLX2) and methyl [35] , Mira [47] , steroid receptor RNA activator (SRA) [44] , and Evf-2 [46] } physically interact with and recruit transcriptional activators [e.g., the WD repeat-containing protein 5 (WDR5) subunit of the mixed lineage leukemia-1 (MLL) complex] to promote target gene activation. This type of activation is achieved, so far, only by polyadenylated ncRNAs, and can function either in cis (e.g., HOTTIP) or in trans (e.g., SRA). (B) Another group of ncRNAs (e.g., noncoding RNAs activating, ncRNA-a) can modulate chromatin looping between enhancers and promoters through interacting with and recruiting or stabilizing the looping factors (e.g., Mediator and cohesin complexes). This is similar to the mechanism of some estrogen-induced enhancer-derived RNAs (eRNAs; Figure 2B ) for gene activation. (C) Under some circumstances, some ncRNAs (Braveheart [53] , Jpx [51, 52] ) can abolish the effects of transcriptional repressors by titrating them away from the promoters of target genes.
Trends in Biochemical Sciences April 2014, Vol. 39, No. 4 CpG binding protein 2 (MECP2) to regulate expression of the neighboring Dlx5/6 genes [45, 46] . Another recent example is HOTTIP (HOXA transcript at the distal tip), which drives the transcriptional activation of the homeobox A (HOXA) gene cluster by directly interacting with the WD repeat-containing protein 5 (WDR5) subunit of the MLL methyltransferase complex, leading to deposition of active promoter histone mark, H3K4me 3 , at target genes [35] . Consistent with this, the MLL complex can also be recruited by Mistral (Mira) ncRNA to activate homeobox A 6 (HOXa6) and HOXa7 during stem cell differentiation [47] and by NeST (Nettoie Salmonella pas Theiler's) ncRNA to activate the interferon-gamma locus [48] .
The second category of activating ncRNAs is exemplified by ncRNA-a (noncoding RNAs activating; Figure 4B ) [43] . This group of ncRNAs regulates gene activation through a distance by recruiting the Mediator complex to, and controlling the phosphorylation of histone H3S10 at its target gene promoter [49] . Intriguingly, ncRNAs might, in specific circumstances, indirectly recruit complexes that exert functions in enhancer-promoter looping [50] .
Finally, the third type of activating mechanism can be summarized as an 'eviction' model ( Figure 4C ), which is exemplified by X chromosome inactivation (XCI). The Xist gene initiates XCI, and is only expressed when more than one X chromosome is present. At the pre-XCI stage, Xist is silenced by the binding of CCCTC-binding factor (CTCF) at its promoter. At the onset of XCI, a ncRNA transcript Jpx is upregulated from both X chromosomes, which directly binds to CTCF and titrates it away from the Xist promoter. This allows expression of Xist to initiate XCI on one of the X chromosomes [51, 52] . Similarly, activation of lineage-specific genes during cardiovascular development requires the removal of polycomb repressive complexes (PRC2) and H3K27me 3 marks from those gene promoters. This process depends on the ncRNA Braveheart, which binds to the suppressor of Zeste 12 (SUZ12) subunit of PRC2 and titrates the whole PRC2 complex away [53] .
Together these data suggest a complex network of interaction between ncRNA and regulatory protein machineries to precisely control gene transcription programs. Although the list of proteins that interact with ncRNAs is still limited (e.g., PRC1/2 and MLL), significant growth of this list is very likely in the near future because many transcriptional regulators may contain RNA binding domains [54] .
Concluding remarks
A detailed understanding of the molecular mechanisms by which enhancers become activated as transcription units remains an important question. For example, what is the mechanism underlying biogenesis and regulation of eRNAs? Is the transcription machinery on enhancers identical to that on promoters? The precise initiation site of enhancer transcription, and the mechanisms that determine elongation and termination, can be approached with contemporary technologies. For example, 5
0 RNA cap site analysis by GRO-seq and PRO-seq [31, 55, 56] could help delineate distinctive features of the TSSs of protein-coding genes, ncRNAs, 1D-eRNAs, and 2D-eRNAs.
A corollary issue is whether eRNAs play general roles in enhancer function. For those enhancers in which it exerts a functional role, we also need a deeper understanding of their mechanism of action. In view of the multiple mechanisms of action described thus far for lncRNAs, similar complexity may be expected for the action mechanisms of eRNAs. Given the initial evidence for roles of eRNAs in enhancer/promoter interactions, it will be of particular interest to systematically examine the consequences of loss of eRNA function on short-and long-range interactions of enhancers with coding gene promoters and other enhancers [57] .
Although the evidence suggests that eRNA transcripts per se and eRNA transcription can both play certain functional roles, it is currently not clear whether these functions are primarily performed in trans or in cis. Current findings regarding eRNAs -their low copy numbers per cell [13, 25] , the predominant absence of eRNA localization at other genomic regions, and the minimal effect of eRNA knockdown on expression of genes on different chromosomes [28] -are most consistent with function in cis ( Figure 5A ). Similar conclusions were made for activating lncRNA [35, 58] . Although depletions of lncRNAs were sufficient to decrease expression of their target genes, ectopic expressions of lncRNAs had minimal effect on target gene expression at the endogenous loci [35, 58] . This points to activity in cis, where lncRNAs are likely to exert function within a domain consisting of interactions between neighboring and distal genomic regions (i.e., intrachromasomal interactions) refined within a close 3D space.
Whether lncRNA and eRNA mediate expression of other genes in trans within the 'interacting domain' has not been systemically addressed ( Figure 5D ). Several observations suggest this possibility. ncRNA-a depletion resulted in a greater number of changes in gene expression than would be accounted for by its target protein-coding gene alone [43] . This suggests trans activity, although the results could be confounded by secondary effects (i.e., changes in other unforeseen cis-regulated direct target genes) ( Figure 5C ). The observations that eRNA contributes to chromatin looping [28] and RNA PolII loading at target gene promoters [34] raised an intriguing possibility of trans function within the 'interacting domain' that has not been ruled out by current studies.
Elucidating the cis versus trans mechanism of eRNA and lncRNA helps tease out allelic specificity in gene regulation, which is an important component of understanding genetic diseases and therapeutic applicability. Further understanding of the 3D organization of the genome and genomic localization of eRNA or lncRNA by identifying RNA-chromatin association will be informative (Table 2) . Given the rapid technological advances in genome editing [59, 60] , it is now feasible to investigate the in cis and in trans mechanism by examining allelic specificity with carefully designed genetic experiments or genome editing experiments coupled with sequencing modalities.
eRNAs that contribute to enhancer activity presumably do so by interacting with other effector molecules. One approach to investigating the function of a particular eRNA will be to identify the factors it interacts with biochemically. At a more general level, efforts have been made to delineate the dependence of activating ncRNAs on substructure to interact with cofactors. For instance, the RNA motifs of the RNA coactivator SRA are critical for its coactivation function [61] . Case studies of other RNA species indicate that simple secondary structures (e.g., tandem stem loops) enable protein-RNA complex formation [62, 63] . Additionally, repeat elements or GC-rich sequences in ncRNAs have been implicated in gene regulation in trans through RNA-DNA-DNA triplex formation with similar elements at promoters of target genes [63] [64] [65] . As progress is made in understanding protein-RNA binding specificity and RNA secondary structures [54, 66] , a major challenge will be to elucidate hidden sequence or structural codes underlying the behaviors of different types of ncRNAs in interacting with their protein partners.
Finally, given increasing evidence that a majority of disease-associated loci represent sequence variations in enhancers [4, 5, [67] [68] [69] , a major question is whether it will be feasible to alter enhancer function for therapeutic purposes. Advances in antisense oligonucleotide-based methods that target nuclear RNAs in vivo could potentially be applied to knockdown cell type-specific eRNAs as a means to modulate coding gene expression in a cell-specific manner [31, 70] . In addition, enhancers harboring cohorts of transcription co-regulatory complexes could be major targets of therapeutic small molecules that modulate specific classes of epigenetic regulators. The further exploration of enhancer transcription and functional roles of eRNAs will therefore not only be of central importance for the further understanding of regulation of gene expression in homeostasis and development, but also for advancing novel therapeutic interventions for human diseases. 
